Using an orthotopic model of breast cancer (low Her2), 267/Dt combinations were found to exert enhanced therapeutic activity, as demonstrated by significantly reduced tumor growth and extended survival in mice treated with the combination compared to the single agents. Here, ERBB2 is linked to breast cancer.